2009, Number 90
<< Back Next >>
Rev Enfer Infec Pediatr 2009; 22.23 (90)
Evaluación del tratamiento de la varicela con ribavirina o metisoprinol en niños
Becerril PR, Reyes BME, Fuentes CMC, Garibay VM
Language: Spanish
References: 24
Page: 41-47
PDF size: 145.43 Kb.
ABSTRACT
Background: Ribavirin (RB) has demonstrated antiviral activity against varicella-zoster virus VZV in immunocompetent and immunocompromised children. Metisoprinol (MET) has claimed to have antiviral proprieties against VZV.
Objective: To evaluate the antiviral efficacy of oral RB and MET in varicella.
Methods: A prospective, longitudinal, comparative single blind study with RB (n=33) and MET (n=34). There were no statistical differences between groups at baseline. The study included 67 healthy children between 2 and 10 years old, with clinical diagnosis of varicella, with less than 48 hours of start of disease. An informed consent by the parents/tutors was included to the study. Patients were evaluated every day for the first eight days and every other day up to 18 days. Along the observation period, the presence of fever, malaise, pruritus, number of vesicles, crops and crust formation were recorded. Patients were randomly assigned to treatment group: group A received RB 20 mg/kg/day, and group B received MET 100 mg/kg/day, both treatments by oral route for a five days period.
Results: The number of vesicles at day five were 12.24 ± 32.84 vs. 59.03 ± 118.09 (p=0.032) for RB and MET, respectively. The number of patients with new crops decreased significantly at day four in RB group 1/33 (3.03%) vs. MET 7/34 (20.58%) (p=0.03). Patients without pruritus at day five were 29/31 (93.5%) for RB vs. 22/31 (71.0%) for MET (p=0.02). Malaise disappeared at day two in 16/19 (84.2%) patients of RB vs. 10/21 (47.6%) of MET (p=0.017).
Conclusion: In our study, RB decreased the number of lesions, the number of patients with new crops, and reduced malaise and can be considered as an effective treatment of varicella. Metisoprinol did not show a favorable effect on the clinical evolution of varicella and should not be considered as a treatment for this disease in otherwise healthy children.
REFERENCES
Whitley RJ. Varicella-Zoster virus infections. En: Galasso GJ, Whitley RJ, Merigan TC (eds.). Antiviral agents and human viral diseases. 4ª edición. Estados Unidos: Lippincott-Raven; 1997. p. 279-305.
Cohen JI, Straus SE. Varicella-Zoster virus and its replication. En: Fields BN, Knipe DM, Howley PM (eds). Fields virology. 3ª edición. Estados Unidos: Lippincott-Raven; 1996. p. 2525-45.
Arbin AM. Varicella-Zoster virus. En: Fields BN, Knipe DM, Howley PM (eds). Fields virology. 3ª edición. Estados Unidos: Lippincott-Raven. 1996. p. 2546-85.
SSA. Informacion Epidemiologica de Morbilidad 2007. Internet. En línea, disponible en: http://dgepisalud.gob.mx/anuario/html/anuarios html. Consultado el 19 de marzo de 2009.
Gonzalez N, Saltigeral P, Castañeda JL, Hernandez M. Tratamiento con ribavirina en niños con varicela. Revista de Enfermedades Infecciosas en Pediatria 1988;1(6):212-5.
Arredondo GJL, Sánchez TMI, Paquentin AJ. Tratamiento de la varicela con ribavirina estudio doble ciego. IMI 1988;15:248-52.
Dillman C, Lozano V, Garibay M, Fortuño V. Tratamiento de la varicela con ribavirina en niños inmunodeprimidos. Revista de Enfermedades Infecciosas en Pediatria 1990;IV(14):41-52.
Kalimo KO, Joronen IA, Havu VK. Failure of oral inosiplex treatment of recurrent herpes simplex virus infections. Arch Dermatol 1983;119(6):463-7.
Payne CM, Menday AP, Rogers T, Staughton RC. Isoprinosine does not influence the natural history of herpes zoster or postherpetic neuralgia. Scand J Infect Dis 1989;21(1):15-8.
Ferrer GR. Ribavirin in varicella. 1977. (Trabajo no publicado).
Llorens TF. Tratamiento de la varicela con ribavirina. Estudio de efectividad en población abierta. Rev Mexicana de Pediatría 1996;63(6):269-74.
Becerril PR, Perez IV, Reyes BME, Salgado CM, De Hoyos G, Rivera CR, et al. Evaluación del tratamiento de la varicela con ribavirina o aciclovir en niños. Rev Enfermedades Infecciosas en Pediatria 2009;16(63):86-94.
Renoux G, Renoux M, Guillaumin JM. Isoprinosine as an immunopotentiator. J Immunopharmacol 1979;1(3):337-56.
Hersey P, Bindon C, Bradley M, Hasic E. Effect of isoprinosine on interleukin 1 and 2 production and on suppressor cell activity in pokeweed mitogen stimulated cultures of B and T cells. Int J Immunopharmacol 1984;6(4):321-8.
Chang TW, Heel RC. Ribavirin and inosiplex: a review of their present status in viral diseases. Drugs 1981;22(2):111-28.
Huttenlocher PR, Mattson RH. Isoprinosine in subacute sclerosing panencephalitis. Neurology 1979;29(6):763-71.
Jenson HB, Leach CT. Chickenpox and Zoster. Pediatric Infectious Diseases Principles and Practice 2002:331-42.
Galli M, Lazzarin A, Moroni M, Zanussi C. Inosiplex in recurrent herpes simplex infections. Lancet 1982 7;2(8293):331-2.
Nekam K, Torok K, Lang I, Gergely P, Petranyi G. Isoprinosine: therapeutic action and studies in recurrent herpes. Orv Hetil 1980;121(23):1393-5.
Feldman S, Hayes FA, Chaudhary S, Ossi M. Inosiplex for localized herpes zoster in childhood cancer patients: preliminary controlled study. Antimicrob Agents Chemother 1978;14(3):495-7.
Gershan AA, La Russa P. Varicella. Krugman’s (eds.). Infectious diseases of children. 10ª edición. Estados Unidos: Mosby. 1998. p. 620-49.
Paganini H. Varicela. En: Infectología Pediátrica. 1ª edición. México: Científica Interamericana. 2007. p. 1098-105.
Lawrence DW. Varicella - Zoster Virus. Lange Current Diagnosis & Treatment in Infectious Diseases. México: McGraw-Hill; 2001. p. 404-6.
Martínez RE, Deveaux J. Varicela. En: Infectología Clínica Pediátrica. 4ª edición. México: Editorial Trillas; 1991. p. 360-71.